Autologous hematopoietic stem cell transplantation with concomitant SARS-CoV-2 infection

Knaus, Hanna A.; Rabitsch, Werner; Buchtele, Nina; Cserna, Julia; Wohlfarth, Philipp

doi:10.1007/s00277-021-04680-z

Cited by 6 publications

(7 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 19 Previous case reports have demonstrated that patients who had COVID-19 infection prior to undergoing transplantation did not encounter any instances of reinfection, reactivation, or COVID-19-associated complications post-transplantation. 20 21 22 23 24 25 26 In accordance with the aforementioned cases, we did not detect any COVID-19-associated complications following transplantation in our study.…”

supporting

confidence: 90%

Comparison of the Clinical Outcomes Between Early and Delayed Transplantation After SARS-CoV-2 Infection

Ra,

Kim,

Jang

et al. 2024

J Korean Med Sci

View full text Add to dashboard Cite

Our study analyzed 95 solid organ transplant (SOT) and 78 hematopoietic stem cell transplant (HSCT) recipients with prior coronavirus disease 2019 (COVID-19). Patients who underwent transplantation within 30 days of COVID-19 infection comprised the early group, and those who underwent transplantation post-30 days of COVID-19 infection comprised the delayed group. In the early transplantation group, no patient, whether undergoing SOT and HSCT, experienced COVID-19-associated complications. In the delayed transplantation group, one patient each from SOT and HSCT experienced COVID-19-associated complications. Additionally, among early SOT and HSCT recipients, two and six patients underwent transplantation within seven days of COVID-19 diagnosis, respectively. However, no significant differences were observed in the clinical outcomes of these patients compared to those in other patients. Early transplantation following severe acute respiratory syndrome coronavirus 2 infection can be performed without increased risk of COVID-19-associated complications. Therefore, transplantation needs not be delayed by COVID-19 infection.

show abstract

supporting

confidence: 90%

Comparison of the Clinical Outcomes Between Early and Delayed Transplantation After SARS-CoV-2 Infection

Ra,

Kim,

Jang

et al. 2024

J Korean Med Sci

View full text Add to dashboard Cite

show abstract

“…Lastly, several reports have been described regarding HCT patients that have been diagnosed with COVID-19 in the cytopenic phase prior to initial engraftment. Although these studies did not meet the eligibility criteria for inclusion, they highlight the continued need for stringent, preventative measures at transplant centers to prevent SARS-CoV-2 infections in this vulnerable patient population [ 10 , 53 , 54 ].…”

Section: Discussionmentioning

confidence: 99%

“…However, many people with COVID-19 remain asymptomatic [ 9 ]. While the testing and screening of patients before HCT is commonly performed, it remains possible for patients undergoing HCT to acquire SARS-CoV-2 and develop symptoms of COVID-19 [ 10 ]. To provide optimal care for patients and maintain access to transplanting through fully functional programs and services at transplant centers, it is necessary to have an up-to-date understanding of the clinical manifestations in this vulnerable patient population.…”

Section: Introductionmentioning

confidence: 99%

A Portrait of SARS-CoV-2 Infection in Patients Undergoing Hematopoietic Cell Transplantation: A Systematic Review of the Literature

et al. 2022

View full text Add to dashboard Cite

The management of COVID-19 in hematopoietic cell transplant (HCT) recipients represents a special challenge given the variable states of immune dysregulation and altered vaccine efficacy in this population. A systematic search (Ovid Medline and Embase on 1 June 2021) was needed to better understand the presenting features, prognostic factors, and treatment options. Of 897 records, 29 studies were identified in our search. Most studies reporting on adults and pediatric recipients described signs and symptoms that were typical of COVID-19. Overall, the mortality rates were high, with 21% of adults and 6% of pediatric HCT recipients succumbing to COVID-19. The factors reported to be associated with increased mortality included age (HR = 1.21, 95% CI 1.03–1.43, p = 0.02), ICU admission (HR = 4.42, 95% CI 2.25–8.65, p < 0.001 and HR = 2.26, 95% CI 1.22–4.20, p = 0.01 for allogeneic and autologous HCT recipients), and low platelet count (OR = 21.37, 95% CI 1.71–267.11, p = 0.01). Performance status was associated with decreased mortality (HR = 0.83, 95% CI 0.74–0.93, p = 0.001). A broad range of treatments was described, although no controlled studies were identified. The risk of bias, using the Newcastle–Ottawa scale, was low. Patients undergoing HCT are at a high risk of severe morbidity and mortality associated with COVID-19. Controlled studies investigating potential treatments are required to determine the efficacy and safety in this population.

show abstract

“…To the best of our knowledge 3 cases were previously reported of COVID-19 in the context of ASCT [8] , [9] , [10] , none were recorded in an autoimmune disease setting. Our case may show the impact of COVID-19 on ASCT recipients during the period of immune reconstitution.…”

Section: Discussionmentioning

confidence: 88%

COVID-19 in the context of autologous hematopoietic stem cell transplantation for a patient with autoimmune disease

Alsuliman

Stocker

Wyngaert

et al. 2022

Current Research in Translational Medicine

View full text Add to dashboard Cite

Autologous hematopoietic stem cell transplantation with concomitant SARS-CoV-2 infection

Cited by 6 publications

References 10 publications

Comparison of the Clinical Outcomes Between Early and Delayed Transplantation After SARS-CoV-2 Infection

Comparison of the Clinical Outcomes Between Early and Delayed Transplantation After SARS-CoV-2 Infection

A Portrait of SARS-CoV-2 Infection in Patients Undergoing Hematopoietic Cell Transplantation: A Systematic Review of the Literature

COVID-19 in the context of autologous hematopoietic stem cell transplantation for a patient with autoimmune disease

Contact Info

Product

Resources

About